Insights Into Multiple (MM)

Perspectives on current treatment practices regarding frontline therapy of multiple myeloma (MM), the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents

Southwest February 23, 2021

Faculty Chair

Rafael Fonseca, MD

Mayo Clinic, Phoenix, AZ

Central March 29, 2021

Faculty Chair

Rafael Fonseca, MD

Mayo Clinic, Phoenix, AZ

More Information

  • Virtual Series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual Series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of multiple myeloma
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.